Therapy with lopinavir/ritonavir and hydroxychloroquine is associated with acute kidney injury in COVID-19 patients

BACKGROUND: Acute kidney injury (AKI) is an independent risk factor for mortality, which affects about 5% of hospitalized coronavirus disease-2019 (COVID-19) patients and up to 25–29% of severely ill COVID-19 patients. Lopinavir/ritonavir and hydroxychloroquine show in vitro activity against severe...

Descripción completa

Detalles Bibliográficos
Autores principales: Schneider, Johanna, Jaenigen, Bernd, Wagner, Dirk, Rieg, Siegbert, Hornuss, Daniel, Biever, Paul M., Kern, Winfried V., Walz, Gerd
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8112697/
https://www.ncbi.nlm.nih.gov/pubmed/33974624
http://dx.doi.org/10.1371/journal.pone.0249760

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8112697/
https://www.ncbi.nlm.nih.gov/pubmed/33974624
http://dx.doi.org/10.1371/journal.pone.0249760

Ejemplares similares